REYON PHARMACEUTICAL CO., LTD To acquire KRW 950.0 million of 3rd convertible bonds before maturity
REYON PHARMACEUTICAL CO., LTD· Material Event Report
RAI summary · Not investment advice
REYON PHARMACEUTICAL CO., LTD will acquire KRW 950.0 million of its 3rd convertible bonds before maturity after talks with the holder, leaving KRW 84.0 billion outstanding.
Face value acquired
KRW 950.0 million
0.52% of total shares · handling to be decided later by the board
Key facts
- Bond type
- 3rd unsecured private convertible bonds
- Bond issue date
- Oct 25, 2024
- Maturity date
- Oct 25, 2029
- Total face value
- KRW 85.0 billion
- Acquisition amount
- KRW 1.0 billionPrincipal and interest
- Acquisition method
- Off-market purchase
- Reason for acquisition
- Decision to acquire bonds before maturity through talks with the bondholder
- Plan for acquired bonds
- To be decided later by board resolution
- Remaining bonds after acquisition
- KRW 84.0 billion
- Conversion price per share
- KRW 9,795
- Convertible shares
- 96,988 shares
- % of total shares
- 0.52%
Earlier Material Event Report filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.022026.11.02 | Material Event Report | KRW 3.0 billion |
| 26.10.272026.10.27 | [Amended] Material Event Report | KRW 9.0 billion · 4.54% of total shares · 49.15% including outstanding bonds · changed from KRW 10.0 billion |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist